Integra Lifesciences Q3 revenue slightly misses estimates on flood damage
IART•Integra Lifesciences reported Q3 revenue of $411.2 million, slightly below the $414.12 million estimate, while adjusted EPS of $0.59 beat estimates. The company cited $7 million in lost revenue from Cincinnati flood damage and expects Q4 revenue of $413 million to $433 million.
1. Quarterly results
Q3 revenue grew 2.3% to $411.2 million, slightly missing the $414.12 million analyst estimate. Adjusted EPS was $0.59, above the $0.56 estimate; reported EPS was $0.19.
2. Flood and segment performance
The company said flood damage at its Cincinnati facility reduced Q3 revenue by $7 million. Specialty Surgery performed more strongly, led by Neurosurgery products, while Tissue Reconstruction declined.
3. Company outlook
Integra expects Q4 revenue of $413 million to $433 million and adjusted EPS of $0.61 to $0.71. Its 2026 revenue outlook is $1.634 billion to $1.654 billion.
